US/UK/Canada

Share

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Pick a time period -
Tags ( Active)

Inhalation Sciences AB (publ) releases Annual Report 2023

Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO comments 2023 was another year in which we continued to take new market share and successfully deliver on our strategic goals. Over the past three years, revenue has increased steadily by 29% from 2021 to 2022 and now by 44% from 2022 to 2023. At the same time, we have also significantly improved our operating profit during the same period. With this positive development, we

Inhalation Sciences to present at FDA’s public workshop GDUFA on May 20th, 2024

Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic Drug User Fee Amendments) on May 20[th], 2024.The annual GDUFA Public Workshop is open and free to the public, and any member of the public may provide comments to the docket for the meeting or may provide their public comments in a prepared presentation, or as impromptu comments. The FDA routinely announces the workshop and provides information about how the public may provide comments. This includes information about how the public can submit a

Inhalation Sciences AB (publ) releases Q1 Report 2023

(Stockholm, Sweden, 31 May 2023) Inhalation Sciences AB announces that its Q1 Report for 2023 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/CEO statement We started the year with a strong order backlog that was the result of a successful closing of sales in 2022. Operationally, our focus has been on meeting the increased order intake and delivering projects to our customers of the highest quality. Revenues in the first quarter increased by 57% compared to the same period last year and

Inhalation Research Services signs CRO contract worth 898 000 SEK with ISR Immune System Regulation AB for part of toxicology program on new inhaled COVID-19 vaccine

(Stockholm June 18, 2021) Inhalation Research Services (IRS), the contract research organization of Inhalation Sciences AB, has signed a contract with Stockholm-based research company ISR Immune System Regulation AB worth 898 000 SEK. The contract is for part of the toxicology program of a novel inhaled vaccine against SARS-CoV-2, the virus that causes COIVD-19.ISR Immune System Regulation AB is an innovation-focused preclinical and clinical research company based in Sweden developing novel drugs with a focus on immunotherapy. The contract research order is for the initial part of the

Inhalation Sciences Sweden AB (publ) releases Interim Report Q2, January 1- June 30, 2020

(Stockholm, Sweden, August 26, 2020) During the second quarter 2020, Inhalation Sciences AB sold all its remaining shares in Ziccum AB for a total value of approximately SEK 21.2 million after selling expenses; it signed a global distribution agreement with TSE Systems GMBH, with an agreement to purchase at least three PreciseInhale® instruments, with associated modules, at an agreed minimum order value of SEK 3 million; it received a new contract research (Inhalation Research Services) assignment worth approx. SEK 0.8 million which will be performed using ISAB's leading in vitro dissolution

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe